Latest Hotspot

NeuroBo, Dong-A ST, & ImmunoForge Collaborate on Monthly Obesity Treatment DA-1726

9 August 2024
3 min read

NeuroBo Pharmaceuticals, Inc., a biotechnology enterprise in the clinical stages, dedicated to advancing treatments for cardiometabolic disorders, has declared the signing of a collaborative research agreement with Dong-A ST Co. Ltd. and ImmunoForge. The collaboration aims to develop a long-acting, once-monthly formulation of DA-1726, a new dual oxyntomodulin analog agonist that targets both the glucagon-like peptide-1 receptor (GLP1R) and the glucagon receptor (GCGR).

👇Discover comprehensive information about this drug, from its R&D status, core patents, clinical trials to approval status in global countries, by simply clicking on the image below. Dive deep into our drug database now.

图形用户界面, 应用程序

描述已自动生成

Hyung Heon Kim, President and CEO of NeuroBo, announced, “The execution of this research agreement, in partnership with Dong-A ST and ImmunoForge, marks an important step towards the potential creation of a long-acting version of DA-1726. This would improve patient adherence and simplify the administration process for obesity treatment.” He further explained, “We are optimistic that ImmunoForge’s ELP platform technology could transform DA-1726, currently undergoing Phase 1 trials, into a once-a-month injection, addressing the challenges of converting peptides like DA-1726 into extended-release formats. We anticipate close cooperation with Dong-A ST and ImmunoForge to develop a pioneering, monthly obesity treatment option.”

Sung-Min Ahn and Kiho Chang, Co-CEOs of ImmunoForge, added, “This partnership with top-tier pharmaceutical leader Dong-A ST and NeuroBo highlights the promise of our ELP platform technology. Our patented once-monthly, long-acting ELP platform technology has the potential to extend a drug's half-life up to 200-fold, and we are eager to investigate its potential with NeuroBo’s DA-1726, a promising approach for obesity treatment.”

DA-1726 is a novel oxyntomodulin analogue acting as a GLP1R/GCGR dual agonist, designated for weekly subcutaneous administration for addressing obesity and Metabolic Dysfunction-Associated Steatohepatitis. This dual agonist of GLP-1 and glucagon receptors promotes weight reduction by decreasing appetite and boosting energy use. Pre-clinical mouse studies have shown that DA-1726 leads to better weight loss than semaglutide and cotadutide. Additionally, compared to tirzepatide and survodutide in pre-clinical mouse models, DA-1726 demonstrated equivalent weight reduction with higher food intake, while also preserving lean mass and showing superior lipid-lowering effects compared to survodutide.

👇Explore the latest research progress on drug-related developments, indications, therapeutic organizations, clinical trials, results, and patents by clicking on the targeted picture link below. Unfold a world of comprehensive information on this target in just a click!

图形用户界面

描述已自动生成

According to the data provided by the Synapse Database, As of August 9, 2024, there are 50 investigational drugs for the GLP1R/GCGR targets, including 29 indications, 57 R&D institutions involved, with related clinical trials reaching 194, and as many as 2623 patents.

DA-1726 is a synthetic peptide drug with a focus on addressing digestive system disorders, endocrinology, and metabolic diseases. The drug is currently in Phase 1 of development and is being investigated for its potential to treat nonalcoholic steatohepatitis, obesity, and diabetes mellitus. Further research and clinical trials are necessary to determine the efficacy and safety of DA-1726 in addressing these medical conditions.

图形用户界面, 文本, 应用程序

描述已自动生成

Pharma Frontiers: Daily Digest of Global Pharmaceutical News – Aug 9
Pharma Frontiers
12 min read
Pharma Frontiers: Daily Digest of Global Pharmaceutical News – Aug 9
9 August 2024
Aug 9th latest updates in the global new drug development field, including progress in new drug research and development, transaction information, and partnership developments.
Read →
First U.S. Participant Joins Global Clinical Trial for Telitacicept in Myasthenia Gravis: A Milestone
Latest Hotspot
3 min read
First U.S. Participant Joins Global Clinical Trial for Telitacicept in Myasthenia Gravis: A Milestone
9 August 2024
The initial participant in the U.S. joins the phase III global multi-center clinical trial for telitacicept targeting myasthenia gravis, marking a significant milestone.
Read →
Elevation Oncology's Phase 1 Trial: Promising Early Results for EO-3021 in Advanced Non-Resectable/Metastatic Solid Tumors
Latest Hotspot
3 min read
Elevation Oncology's Phase 1 Trial: Promising Early Results for EO-3021 in Advanced Non-Resectable/Metastatic Solid Tumors
9 August 2024
Elevation Oncology Releases Encouraging Early Results from Phase 1 Trial of EO-3021 in Patients with Advanced Non-Resectable or Metastatic Solid Tumors.
Read →
Daiichi Sankyo and Merck Sign Global Pact for MK-6070 Development and Sales
Latest Hotspot
3 min read
Daiichi Sankyo and Merck Sign Global Pact for MK-6070 Development and Sales
9 August 2024
This expansion now encompasses Merck’s investigational product MK-6070, a T-cell engager targeting delta-like ligand 3 (DLL3).
Read →
Get started for free today!
Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.
Start your data trial now!
Synapse data is also accessible to external entities via APIs or data packages. Empower better decisions with the latest in pharmaceutical intelligence.